Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01767194




Registration number
NCT01767194
Ethics application status
Date submitted
9/01/2013
Date registered
14/01/2013
Date last updated
24/10/2022

Titles & IDs
Public title
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Scientific title
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Secondary ID [1] 0 0
NCI-2012-03125
Secondary ID [2] 0 0
NCI-2012-03125
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ganglioneuroblastoma 0 0
Recurrent Neuroblastoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Cancer 0 0 0 0
Children's - Other
Cancer 0 0 0 0
Children's - Brain
Cancer 0 0 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Dinutuximab
Treatment: Drugs - Irinotecan Hydrochloride
Other interventions - Laboratory Biomarker Analysis
Other interventions - Sargramostim
Treatment: Drugs - Temozolomide
Treatment: Drugs - Temsirolimus

Experimental: Arm I (temozolomide, irinotecan hydrochloride, temsirolimus) - CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.

Experimental: Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) - Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.


Other interventions: Dinutuximab
Given IV

Treatment: Drugs: Irinotecan Hydrochloride
Given IV

Other interventions: Laboratory Biomarker Analysis
Optional correlative studies

Other interventions: Sargramostim
Given SC or IV

Treatment: Drugs: Temozolomide
Given PO

Treatment: Drugs: Temsirolimus
Given IV
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Randomized Patients Who Are Responders
Timepoint [1] 0 0
Up to the first 6 cycles of treatment
Primary outcome [2] 0 0
Percentage of Patients in the Dinutuximab Arm Who Are Responders
Timepoint [2] 0 0
Up to the first 6 cycles of treatment

Eligibility
Key inclusion criteria
- Patients must have had histologic verification of neuroblastoma or
ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with
elevated urinary catecholamines (i.e., > 2 x upper limit of normal [ULN]), at the time
of initial diagnosis

- For the purposes of this study, aggressive multidrug chemotherapy is defined as
chemotherapy including 2 or more agents that must include an alkylating agent and a
platinum-containing compound; patients must have ONE of the following:

- First episode of recurrent disease following completion of aggressive multi-drug
frontline therapy

- First episode of progressive disease during aggressive multi-drug frontline
therapy

- Primary resistant/refractory disease (less than partial response by INRC)
detected at the conclusion of at least 4 cycles of aggressive multidrug induction
chemotherapy on or according to a high-risk neuroblastoma protocol (examples
include A3973, ANBL0532, ANBL09P1, etc.)

- Patients must have at least ONE of the following:

- Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT)
scan obtained within 3 weeks prior to study entry; measurable is defined as >= 10
mm in at least one dimension on spiral/helical CT that is metaiodobenzylguanidine
(MIBG) avid or demonstrates increased fludeoxyglucose (FDG) uptake on positron
emission tomography (PET) scan

- MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a
minimum of one site; this site must represent disease recurrence after completion
of therapy, progressive disease on therapy, or refractory disease during
induction

- Patients with resistant/refractory soft tissue disease that is not MIBG avid or
does not demonstrate increased FDG uptake on PET scan must undergo biopsy to
document the presence of viable neuroblastoma; biopsy is not required for
patients who have new site of soft tissue disease (radiographic evidence of
disease progression) regardless of whether progression occurs while receiving
therapy or after completion of therapy

- Note: Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow
disease only are NOT eligible for this study

- Patients must have a performance status corresponding to Eastern Cooperative Oncology
Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and
Lansky for patients =< 16 years of age

- Patients must have received frontline therapy (including surgery, chemotherapy,
autologous stem cell transplant [SCT] +/- MIBG, immunotherapy, radiotherapy, and
retinoids) but may NOT have received second line chemotherapy for
resistant/refractory, relapsed disease or progressive disease

- At least 14 days must have elapsed since completion of myelosuppressive therapy

- At least 7 days must have elapsed since the completion of therapy with a
non-myelosuppressive biologic agent or retinoid

- No interim time prior to study entry is required following prior radiation therapy
(RT) for non-target lesions; however, patients must not have received radiation for a
minimum of 4 weeks prior to study entry at the site of any lesion that will be
identified as a target lesion to measure tumor response; lesions that have been
previously radiated cannot be used as target lesions unless there is radiographic
evidence of progression at the site following radiation or a biopsy done following
radiation shows viable neuroblastoma; palliative radiation is allowed to sites that
will not be used to measure response during this study

- Patients are eligible >= 6 weeks after autologous stem cell transplants or stem cell
infusions as long as hematologic and other eligibility criteria have been met

- Patients are eligible >= 6 weeks after therapeutic 131I-MIBG provided that all other
eligibility criteria are met

- Subjects who have previously received anti-GD2 monoclonal antibodies for biologic
therapy or for tumor imaging are eligible unless they have had progressive disease
while receiving prior anti-GD2 therapy; subjects who have received autologous marrow
infusions or autologous stem cell infusions that were purged using monoclonal antibody
linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligible

- Patients must not have received long-acting myeloid growth factors (e.g., Neulasta)
within 14 days of entry on this study; seven days must have elapsed since
administration of a short acting myeloid growth factor

- Peripheral absolute neutrophil count (ANC) >= 750/uL

- Platelet count >= 75,000/uL (transfusion independent)

- Patients known to have bone marrow involvement with neuroblastoma are eligible
provided that minimum ANC and platelet count criteria are met but are not evaluable
for hematological toxicity

- Creatinine clearance or estimated radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or

- A serum creatinine =< upper limit of normal (ULN) based on age/gender as follows:

- Age 1 month to < 6 months: 0.4 for males, 0.4 for females

- Age 6 months to < 1 year: 0.5 for males, 0.5 for females

- Age 1 to < 2 years: 0.6 for males, 0.6 for females

- Age 2 to < 6 years: 0.8 for males, 0.8 for females

- Age 6 to < 10 years: 1 for males, 1 for females

- Age 10 to < 13 years: 1.2 for males, 1.2 for females

- Age 13 to < 16 years: 1.5 for males, 1.4 for females

- Age >= 16 years: 1.7 for males, 1.4 for females

- Total bilirubin =< 1.5 x ULN for age AND

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5.0 x
ULN for age (=< 225 U/L); for the purpose of this study, the ULN for SGPT is 45 U/L

- Adequate central nervous system function defined as:

- Patients with a history of central nervous system (CNS) disease must have no
clinical or radiological evidence of CNS disease at the time of study enrollment

- Patients with seizure disorders may be enrolled if seizures are well controlled
on anticonvulsants

- CNS toxicity =< grade 2

- Shortening fraction of >= 27% by echocardiogram (ECHO) OR

- Ejection fraction >= 50% by ECHO or gated radionuclide study

- Adequate coagulation defined as:

- Prothrombin time (PT) =< 1.2 x upper limit of normal

- Adequate pulmonary function defined as:

- No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen
requirement, and room air pulse oximetry > 94% if there is a clinical indication
for pulse oximetry; normal pulmonary function tests in patients who are capable
of cooperating with testing (including diffusion capacity of the lung of carbon
monoxide [DLCO]) are required if there is a clinical indication for
determination; for patients who do not have respiratory symptoms, full pulmonary
function tests (PFTs) are NOT required
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Men and women of childbearing potential and their partners must agree to use adequate
contraception while enrolled on this study; based on the established teratogenic
potential of alkylating agents, pregnant women will be excluded from this study;
female patients who are lactating must agree to stop breastfeeding or will otherwise
be excluded from this study; females of childbearing potential must have a negative
pregnancy test to be eligible for this study

- Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease
only are NOT eligible for this study

- Patients must have been off pharmacologic doses of systemic steroids for at least 7
days prior to enrollment; patients who require or are likely to require pharmacologic
doses of systemic corticosteroids while receiving treatment on this study are
ineligible; the only exception is for patients known to require 2 mg/kg or less of
hydrocortisone (or an equivalent dose of an alternative corticosteroid) as
premedication for blood product administration in order to avoid allergic transfusion
reactions; the use of conventional doses of inhaled steroids for the treatment of
asthma is permitted, as is the use of physiologic doses of steroids for patients with
known adrenal insufficiency

- Patients must not have received enzyme-inducing anticonvulsants including phenytoin,
phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study
enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin
or levetiracetam will be eligible

- Patients must not have been diagnosed with myelodysplastic syndrome or with any
malignancy other than neuroblastoma

- Patients with symptoms of congestive heart failure are not eligible

- Patients must not have >= grade 2 diarrhea

- Patients must not have uncontrolled infection

- Patients with a history of grade 4 allergic reactions to anti-GD2 antibodies or
reactions that required discontinuation of the anti-GD2 therapy are not eligible

- Patients with a significant intercurrent illness (any ongoing serious medical problem
unrelated to cancer or its treatment) that is not covered by the detailed exclusion
criteria and that is expected to interfere with the action of study agents or to
significantly increase the severity of the toxicities experienced from study treatment
are not eligible

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/02/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/09/2022
Sample size
Target
Accrual to date
Final
73
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [3] 0 0
Royal Children's Hospital-Brisbane - Herston
Recruitment hospital [4] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [5] 0 0
Princess Margaret Hospital for Children - Perth
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
6008 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Hawaii
Country [11] 0 0
United States of America
State/province [11] 0 0
Idaho
Country [12] 0 0
United States of America
State/province [12] 0 0
Illinois
Country [13] 0 0
United States of America
State/province [13] 0 0
Indiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Iowa
Country [15] 0 0
United States of America
State/province [15] 0 0
Kentucky
Country [16] 0 0
United States of America
State/province [16] 0 0
Louisiana
Country [17] 0 0
United States of America
State/province [17] 0 0
Maine
Country [18] 0 0
United States of America
State/province [18] 0 0
Maryland
Country [19] 0 0
United States of America
State/province [19] 0 0
Massachusetts
Country [20] 0 0
United States of America
State/province [20] 0 0
Michigan
Country [21] 0 0
United States of America
State/province [21] 0 0
Minnesota
Country [22] 0 0
United States of America
State/province [22] 0 0
Mississippi
Country [23] 0 0
United States of America
State/province [23] 0 0
Missouri
Country [24] 0 0
United States of America
State/province [24] 0 0
Nebraska
Country [25] 0 0
United States of America
State/province [25] 0 0
Nevada
Country [26] 0 0
United States of America
State/province [26] 0 0
New Hampshire
Country [27] 0 0
United States of America
State/province [27] 0 0
New Jersey
Country [28] 0 0
United States of America
State/province [28] 0 0
New Mexico
Country [29] 0 0
United States of America
State/province [29] 0 0
New York
Country [30] 0 0
United States of America
State/province [30] 0 0
North Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
North Dakota
Country [32] 0 0
United States of America
State/province [32] 0 0
Ohio
Country [33] 0 0
United States of America
State/province [33] 0 0
Oklahoma
Country [34] 0 0
United States of America
State/province [34] 0 0
Oregon
Country [35] 0 0
United States of America
State/province [35] 0 0
Pennsylvania
Country [36] 0 0
United States of America
State/province [36] 0 0
South Carolina
Country [37] 0 0
United States of America
State/province [37] 0 0
South Dakota
Country [38] 0 0
United States of America
State/province [38] 0 0
Tennessee
Country [39] 0 0
United States of America
State/province [39] 0 0
Texas
Country [40] 0 0
United States of America
State/province [40] 0 0
Utah
Country [41] 0 0
United States of America
State/province [41] 0 0
Vermont
Country [42] 0 0
United States of America
State/province [42] 0 0
Virginia
Country [43] 0 0
United States of America
State/province [43] 0 0
Washington
Country [44] 0 0
United States of America
State/province [44] 0 0
West Virginia
Country [45] 0 0
United States of America
State/province [45] 0 0
Wisconsin
Country [46] 0 0
Canada
State/province [46] 0 0
Alberta
Country [47] 0 0
Canada
State/province [47] 0 0
British Columbia
Country [48] 0 0
Canada
State/province [48] 0 0
Manitoba
Country [49] 0 0
Canada
State/province [49] 0 0
Newfoundland and Labrador
Country [50] 0 0
Canada
State/province [50] 0 0
Nova Scotia
Country [51] 0 0
Canada
State/province [51] 0 0
Ontario
Country [52] 0 0
Canada
State/province [52] 0 0
Quebec
Country [53] 0 0
New Zealand
State/province [53] 0 0
Auckland
Country [54] 0 0
New Zealand
State/province [54] 0 0
Christchurch
Country [55] 0 0
Puerto Rico
State/province [55] 0 0
San Juan

Funding & Sponsors
Primary sponsor type
Government body
Name
National Cancer Institute (NCI)
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
United Therapeutics
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide
with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that
has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan
hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and
help kill them or carry tumor-killing substances to them. It is not yet known whether giving
irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more
effective in treating neuroblastoma.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01767194
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Rajen Mody
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries